Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study

Journal of Atherosclerosis and Thrombosis

Online ISSN : 1880-3873
Print ISSN : 1340-3478
ISSN-L : 1340-3478

This article has now been updated. Please use the final version.

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study

Akihiro Nakamura, Yuta Kagaya, Hiroki Saito, Masanori Kanazawa, Kenjiro Sato, Masanobu Miura, Masateru Kondo, Hideaki Endo

Author information

JOURNAL OPEN ACCESS Advance online publication

Article ID: ER63659

DOI https://doi.org/10.5551/jat.ER63659

The final version of this article is now available: Vol. 30 (2023), No. 6 pp. 698-699

Details

Article 1st page

Content from these authors

Cited by (2)

Shun Ishibashi, Hidenori Arai, Koutaro Yokote, et al. Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study. Journal of Atherosclerosis and Thrombosis. 2025, Vol.32, No.2, p.210.

Yida Zhou, Ming Chu. Research Progress of Peroxisome Proliferator-Activated Receptor in Non-Alcoholic Steatohepatitis. Highlights in Science Engineering and Technology. 2025, Vol.144, p.317.

この記事はクリエイティブ・コモンズ [表示 - 非営利 - 継承 4.0 国際]ライセンスの下に提供されています。
https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja

Favorites & Alerts

Related articles

Recently viewed articles

Predecessor

The Journal of Japan Atherosclerosis Society

Top

Register with J-STAGE for free!

Already have an account? Sign in here